<DOC>
	<DOCNO>NCT00931203</DOCNO>
	<brief_summary>This single arm phase II trial combine celecoxib , tegafur-uracil , folinate preoperative radiotherapy patient locally advanced rectal cancer . The primary end point pathological complete response ( pCR ) rate . The secondary endpoint toxicity combine celecoxib chemoradiation , negative resection margin rate , clinical tumor response magnetic resonance imaging ( MRI ) , sphincter preservation rate , disease-free survival overall survival .</brief_summary>
	<brief_title>Trial Celecoxib With Preoperative Chemo- Radiation Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>The primary objective determine pathological complete response ( pCR ) combine preoperative tegafur-uracil , folinate , radiation celecoxib locally advanced rectal cancer . The secondary objective study determine : 1 . Toxicity profile combine celecoxib , tegafur-uracil , folinate preoperative radiation locally advanced rectal cancer . 2 . Negative resection margin ( circumferential resection margin ) rate . 3 . Downstaging rate . 4 . Sphincter preservation rate 5 . Locoregional distant failure rate . 6 . Overall survival</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Patients resectable potentially resectable adenocarcinoma rectum . 2 . Clinical stage Magnetic Resonance Image ( MRI ) pelvis , ultrasonography liver Chest X ray : AJCC T2 N12M0 T34 N02M0 ( patient require divert loop colostomy eligible ) . Nuclear medicine study ( whole body bone scan PET scan ) perform clinically indicate . 3 . Bidimensionally measurable disease MRI , do pelvic array coil intrarectal tube . 4 . Age great 18 year &lt; 80 year , ECOG performance status &lt; 2 5 . Biopsy proven adenocarcinoma , superior margin tumor L5S1 spine junction . 6 . WBC &gt; 3.5 x109/L , neutrophil count &gt; 1.5x109/L , platelet count &gt; 100x109/L , serum bilirubin &lt; 1.25xULN ( upper limit normal ) , AST/ALT &lt; 3x ULN , serum creatinine &lt; 1.25xULN . 7 . Informed consent sign . 1 . Distant metastasis , Prior pelvic irradiation , Inflammatory bowel disease , Medical condition preclude radical therapy . 2 . History malignancy within five year ( except nonmelanoma skin cancer , CIN cervix ) . 3 . Pregnancy . 4 . Hypersensitivity celecoxib , NSAID , sulfonamides 5FU . 5 . Cardiovascular disease like congestive heart failure , symptomatic coronary artery disease , myocardiac infarction . 6 . History peptic ulcer disease NSAIDrelated gastrointestinal bleeding 7 . Use aspirin , NSAID celecoxib two week prior study entry . 8 . Patients take warfarin anticoagulating medicine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>